Sex differences in use of psychotropic drugs and drug-induced side effects in schizophrenia patients: Findings of the Research on Asia Psychotropic Prescription (REAP) studies

Australian and New Zealand Journal of Psychiatry

Volumn 45, Issue 3, 2011, Pages 193-198

  Xiang, Yu Tao ^b,c   Wang, Chuan Yue ^b   Si, Tian Mei ^a   Lee, Edwin Ho Ming ^c   He, Yan Ling ^d   Ungvari, Gabor S ^e   Chiu, Helen F K ^c   Yang, Shu Yu ^f   Chong, Mian Yoon ^g   Shinfuku, Naotaka ^h   Tan, Chay Hoon ⁱ   Kua, Ee Heok ⁱ   Fujii, Senta ^j   Sim, Kang ^k   Yong, K H ^k   Trivedi, Jitendra Kumar ^l   Chung, Eun Kee ^m   Udomratn, Pichet ⁿ   Chee, Kok Yoon ^o   Sartorius, Norman ^p  

^a PEKING UNIVERSITY SIXTH HOSPITAL   (China)

^b CAPITAL MEDICAL UNIVERSITY   (China)

^c CHINESE UNIVERSITY OF HONG KONG   (Hong Kong)

^d SHANGHAI MENTAL HEALTH CENTER   (China)

^e UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

^f TAIPEI CITY HOSPITAL   (Taiwan)

^g CHANG GUNG UNIVERSITY   (Taiwan)

^h SEINAN GAKUIN UNIVERSITY   (Japan)

ⁱ NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

^j Hyogo Institute for Traumatic Stress   (Japan)

^k INSTITUTE OF MENTAL HEALTH   (Singapore)

^l KING GEORGE'S MEDICAL UNIVERSITY   (India)

^m Seoul National University   (South Korea)

ⁿ PRINCE OF SONGKLA UNIVERSITY   (Thailand)

^o HOSPITAL KUALA LUMPUR   (Malaysia)

^p UNIVERSITY OF GENEVA   (Switzerland)

more..

Author keywords

prescription; schizophrenia; sex differences

Indexed keywords

AMISULPRIDE; ARIPIPRAZOLE; CHLORPROMAZINE; CHOLINERGIC RECEPTOR BLOCKING AGENT; CLOZAPINE; MOOD STABILIZER; NEUROLEPTIC AGENT; PSYCHOTROPIC AGENT; QUETIAPINE; RISPERIDONE; ZIPRASIDONE;

ADULT; ARTICLE; ASIA; ASIAN; CATATONIA; CLINICAL TRIAL; DELUSION; DRUG INDUCED DISEASE; DRUG MEGADOSE; EXTRAPYRAMIDAL SYMPTOM; FEMALE; HALLUCINATION; HOSPITAL PATIENT; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NEGATIVE SYNDROME; POLYPHARMACY; PRACTICE GUIDELINE; PRESCRIPTION; SCHIZOPHRENIA; SEX DIFFERENCE; SIDE EFFECT; TARDIVE DYSKINESIA; WEIGHT GAIN;

ADULT; AGE FACTORS; ANTIPSYCHOTIC AGENTS; ASIA; DRUG UTILIZATION; FEMALE; HUMANS; MALE; MIDDLE AGED; QUESTIONNAIRES; SCHIZOPHRENIA; SEX CHARACTERISTICS;

EID: 79952291403     PISSN: 00048674     EISSN: 14401614     Source Type: Journal    
DOI: 10.3109/00048674.2010.538839     Document Type: Article

References (53)

1. Jablensky A, Cole SW. Is the earlier age at onset of schizophrenia in males a confounded finding? Results from a cross-cultural investigation. Br J Psychiatry 1997; 170:234-240. (Pubitemid 27117685)
2. Riecher-Rossler A, Hafner H. Gender aspects in schizophrenia: bridging the border between social and biological psychiatry. Acta Psychiatr Scand Suppl 2000:58-62. (Pubitemid 32115749)
3. Pycha R, Pompili M, Innamorati M et al. Sex and ethnic differences among south Tirolean suicides: a psychological autopsy study. Eur Psychiatry 2009; 24:47-56.
4. Roesch-Ely D, Hornberger E, Weiland S et al. Do sex differences affect prefrontal cortex associated cognition in schizophrenia? Schizophr Res 2009; 107:255-261.
5. Anthony M, Berg MJ. Biologic and molecular mechanisms for sex differences in pharmacokinetics, pharmacodynamics, and pharmacogenetics: Part I. J Women's Health Gend Based Med 2002; 11:601-615. (Pubitemid 35174840)
6. Anthony M, Berg MJ. Biologic and molecular mechanisms for sex differences in pharmacokinetics, pharmacodynamics, and pharmacogenetics: Part II. J Women's Health Gend Based Med 2002; 11:617-629.
7. Seeman MV. Gender differences in the prescribing of antipsychotic drugs. Am J Psychiatry 2004; 161:1324-1333. (Pubitemid 38989084)
8. Melkersson KI, Hulting AL, Rane AJ. Dose requirement and prolactin elevation of antipsychotics in male and female patients with schizophrenia or related psychoses. Br J Clin Pharmacol 2001; 51:317-324. (Pubitemid 32391486)
9. Altamura AC, Sassella F, Santini A, Montresor C, Fumagalli S, Mundo E. Intramuscular preparations of antipsychotics: uses and relevance in clinical practice. Drugs 2003; 63:493-512. (Pubitemid 36337728)
10. Miller MA. Gender-based differences in the toxicity of pharmaceuticals - the Food and Drug Administration's perspective. Int J Toxicol 2001; 20:149-152. (Pubitemid 32646165)
11. Sim K, Su HC, Fujii S, Yang SY et al. High-dose antipsychotic use in schizophrenia: a comparison between the 2001 and 2004 Research on East Asia Psychotropic Prescription (REAP) studies. Br J Clin Pharmacol 2009; 67:110-117.
12. Chong MY, Tan CH, Fujii S et al. Antipsychotic drug prescription for schizophrenia in east Asia: rationale for change. Psychiatry Clin Neurosci 2004; 58:61-67. (Pubitemid 38200373)
13. Shinfuku N, Tan CH. Pharmacotherapy for schizophrenic inpatients in East Asia-changes and challenges. Int Rev Psychiatry 2008; 20:460-468.
14. APA. Practice guideline for the treatment of patients with schizophrenia. Washington, DC: American Psychiatric Press, 1997.
15. Kane JM, Aguglia E, Altamura AC et al. Guidelines for depot antipsychotic treatment in schizophrenia. European Neuropsychopharmacology Consensus Conference in Siena, Italy. Eur Neuropsychopharmacol 1998; 8:55-66.
16. Woods SW. Chlorpromazine equivalent doses for the newer atypical antipsychotics. J Clin Psychiatry 2003; 64:663-667. (Pubitemid 36750143)
17. Chaves AC, Seeman MV. Sex selection bias in schizophrenia antipsychotic trials. J Clin Psychopharmacol 2006; 26:489-494. (Pubitemid 44401469)
18. Xiang YT, Weng YZ, Leung CM, Tang WK, Chan SS, Wang CY, et al. Gender differences in sociodemographic and clinical characteristic and the quality of life of Chinese schizophrenia patients. Aust N Z J Psychiatry 2010; 44:450-455.
19. Peralta V, Cuesta MJ, Caro F, Martinez-Larrea A. Neuroleptic dose and schizophrenic symptoms. A survey of prescribing practices. Acta Psychiatr Scand 1994; 90:354-357. (Pubitemid 24331608)
20. Barbui C, Nose M, Bindman J et al. Sex differences in the subjective tolerability of antipsychotic drugs. J Clin Psychopharmacol 2005; 25:521-526. (Pubitemid 41669042)
21. Goldstein JM, Cohen LS, Horton NJ et al. Sex differences in clinical response to olanzapine compared with haloperidol. Psychiatry Res 2002; 110:27-37. (Pubitemid 34451094)
22. Hafner H. Gender differences in schizophrenia. Psychoneuroendocrinology 2003; 28S2:17-54. (Pubitemid 36335819)
23. Usall J, Araya S, Ochoa S, Busquets E, Gost A, Marquez M. Gender differences in a sample of schizophrenic outpatients. Compr Psychiatry 2001; 42:301-305. (Pubitemid 32656178)
24. Goldstein JM, Link BG. Gender and the expression of schizophrenia. J Psychiatr Res 1988; 22:141-155.
25. Chai HX, Du JH, Wu ZJ. A study of additive effect of sodium valproate in the treatment of schizophrenia (in Chinese). J Clin Psychol Med 2004; 14:151-152.
26. Xiang YT, Weng YZ, Leung CM, Tang WK, Ungvari GS. Long-term use of mood stabilizers and its impact on the quality of life of Chinese patients with schizophrenia. Clin Neuropharmacol 2009; 32:16-21.
27. Wang CY, Luo XN, Liu RG, Tao QN, Zang DX. [The influence of violent behaviour on patients with psychiatric disorder] (in Chinese). Health Psychol 1995; 3:21-22.
28. Citrome L. Use of lithium, carbamazepine, and valproic acid in a state-operated psychiatric hospital. J Pharm Technol 1995; 11:55-59.
29. Chengappa KN, Chalasani L, Brar JS, Parepally H, Houck P, Levine J. Changes in body weight and body mass index among psychiatric patients receiving lithium, valproate, or topiramate: an open-label, nonrandomized chart review. Clin Ther 2002; 24:1576-1584. (Pubitemid 35351843)
30. Chen H, Kennedy WK, Dorfman JH, Fincham JE, Reeves J, Martin BC. The effect of adjunctive mood stabilizers on antipsychotic utilization pattern and health resource utilization for Medicaid enrollees with schizophrenia. Curr Med Res Opin 2007; 23:1351-1365. (Pubitemid 46998444)
31. Zink M, Englisch S, Meyer-Lindenberg A. Polypharmacy in schizophrenia. Curr Opin Psychiatry 2010; 23:103-111.
32. Carpenter WT Jr, Conley RR, Buchanan RW, Breier A, Tamminga CA. Patient response and resource management: another view of clozapine treatment of schizophrenia. Am J Psychiatry 1995; 152:827-832.
33. Kolakowska T, Williams AO, Ardern M et al. Schizophrenia with good and poor outcome. I: early clinical features, response to neuroleptics and signs of organic dysfunction. Br J Psychiatry 1985; 146:229-239.
34. Szymanski S, Lieberman JA, Alvir JM et al. Gender differences in onset of illness, treatment response, course, and biologic indexes in first-episode schizophrenic patients. Am J Psychiatry 1995; 152:698-703.
35. Xiang YT, Wang CY, Weng YZ et al. Sex differences in patients with schizophrenia: a prospective, multi-center study. Psychiatry Res 2010; 177:294-298.
36. Fountoulakis KN, Kantartzis S, Siamouli M et al. Beneficial effect of long-acting injectable risperidone on the neurocognitive deficit of a schizophrenic patient: a case report. Int J Clin Pharmacol Ther 2006; 44:589-592. (Pubitemid 44718195)
37. Xiang YT, Weng YZ, Leung CM, Tang WK, Ungvari GS. Clinical and social correlates with the use of depot antipsychotic drugs in outpatients with schizophrenia in China. Int J Clin Pharmacol Ther 2008; 46:245-251. (Pubitemid 351663161)
38. Meltzer HY, Rabinowitz J, Lee MA et al. Age at onset and gender of schizophrenic patients in relation to neuroleptic resistance. Am J Psychiatry 1997; 154:475-482. (Pubitemid 27147599)
39. Torgalsboen AK. Full recovery from schizophrenia: the prognostic role of premorbid adjustment, symptoms at first admission, precipitating events and gender. Psychiatry Res 1999; 88: 143-152.
40. Lei ZB. [Sex differences in medication-induced side effects] (in Chinese). Adverse Drug React J 2000; 3:177-179.
41. Morgenstern H, Glazer WM. Identifying risk factors for tardive dyskinesia among long-term outpatients maintained with neuroleptic medications. Results of the Yale Tardive Dyskinesia Study. Arch Gen Psychiatry 1993; 50:723-733. (Pubitemid 23263809)
42. Casey DE. Neuroleptic drug-induced extrapyramidal syndromes and tardive dyskinesia. Schizophr Res 1991; 4:109-120.
43. Halbreich U, Kinon BJ, Gilmore JA, Kahn LS. Elevated prolactin levels in patients with schizophrenia: mechanisms and related adverse effects. Psychoneuroendocrinology 2003; 28: S53-67.
44. Limosin F, Gasquet I, Leguay D, Azorin JM, Rouillon F. Body mass index and prevalence of obesity in a French cohort of patients with schizophrenia. Acta Psychiatr Scand 2008; 118:19-25. (Pubitemid 351832023)
45. Wang CY, Xiang YT, Cai ZJ et al. Risperidone maintenance treatment in schizophrenia: a randomized, controlled trial. Am J Psychiatry 2010;.
46. Homel P, Casey D, Allison DB. Changes in body mass index for individuals with and without schizophrenia, 1987-1996. Schizophr Res 2002; 55:277-284.
47. Wirshing DA. Adverse effects of atypical antipsychotics. J Clin Psychiatry 2001; 62S21:7-10. (Pubitemid 32937571)
48. Baptista T. Body weight gain induced by antipsychotic drugs: mechanisms and management. Acta Psychiatr Scand 1999; 100: 3-16. (Pubitemid 29309192)
49. Meyer JM. Effects of atypical antipsychotics on weight and serum lipid levels. J Clin Psychiatry 2001; 62S27:27-34; discussion 40-21.
50. Tan CH, Shinfuku N, Sim K. Psychotropic prescription practices in east Asia: looking back and peering ahead. Curr Opin Psychiatry 2008; 21:645-650.
51. Kang SG, Lee HJ, Park YM et al. Possible association between the -2548A/G polymorphism of the leptin gene and olanzapine-induced weight gain. Prog Neuropsychopharmacol Biol Psychiatry 2008; 32:160-163.
52. Park YM, Chung YC, Lee SH et al. Weight gain associated with the alpha2a-adrenergic receptor -1,291 C/G polymorphism and olanzapine treatment. Am J Med Genet B Neuropsychiatr Genet 2006; 141B:394-397.
53. Taylor D, Paton C, Kerwin R. The Maudsley prescribing guidelines. London: Martin Dunitz, 2003.